A MINI REVIEW ON PROPERTIES, MECHANISM OF ACTION, PHARMACOKINETIC AND PHARMACODYNAMICS AND ANALYTICAL METHODS OF CARIPRAZINE

ALANKAR SHRIVASTAVA; RADHIKA AGGARWAL; RISHI PRATAP SINGH; RAKHI KHABIYA

doi:10.22159/ijap.2023v15i1.46651

Authors

ALANKAR SHRIVASTAVA Department of Pharmaceutical Quality Assurance, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad-Meerut Road, Ghaziabad 201206 https://orcid.org/0000-0003-3284-0445
RADHIKA AGGARWAL Department of Pharmaceutical Quality Assurance, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad-Meerut Road, Ghaziabad 201206
RISHI PRATAP SINGH IIHMR University, Prabhu Dayal Marg, Near Sanganer Airport, Maruti Nagar, Jaipur, Rajasthan 302029
RAKHI KHABIYA Acropolis Institute of Pharmaceutical Education and Research, Indore 453771, India

DOI:

https://doi.org/10.22159/ijap.2023v15i1.46651

Keywords:

Method validation, Properties, Pharmacodynamics, Pharmacokinetics, Analytical methods, Green analytical method

Abstract

Cariprazine (CPZ) being a “D2/D3 receptor partial agonist” is used for schizophrenia treatment. CPZ illustrate different functional study at “dopamine receptors depending on the assay system”. This study elaborate review summarizes the structure–activity relationship (SAR), Mechanism of action (MOA), pharmacokinetics, pharmacodynamics and analytical methods published. CPZ was found to be more effective than risperidone. It was analogus with a remarkably longer time to deteriorate than inactive drug in a long-term, phase III,-deteriorate prevention study. This study elaborate the activating and solemn or sedative properties of first-line oral second generation antipsychotics by explore the rates of adverse effect in product labelling for the indications of schizophrenia and ancillary treatment of major depressive disorder (MDD). The common adverse events reported were extrapyramidal disorder, insomnia, dizziness, solemn, anxiety, vomiting and constipation in “fixed dose study of tested 1.5, 3.0, and 4.5 mg/day”. The presented review explains about biological properties, pharmacokinetics, pharmacodynamics, and analytical methods of CPZ.

Downloads

Download data is not yet available.

References

Carpenter WT Jr, Buchanan RW. Schizophrenia. N Engl J Med. 1994 Mar 10;330(10):681-90. doi: 10.1056/NEJM199403103301006, PMID 8107719.

Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science. 2002 Apr 26;296(5568):692-5. doi: 10.1126/science.1070532, PMID 11976442.

Momtazmanesh S, Zare Shahabadi A, Rezaei N. Cytokine alterations in schizophrenia: an updated review. Front Psychiatry. 2019;10:892. doi: 10.3389/fpsyt.2019.00892, PMID 31908647.

Ventriglio A, Gentile A, Bonfitto I, Stella E, Mari M, Steardo L. Suicide in the early stage of schizophrenia. Front Psychiatry. 2016;7:116. doi: 10.3389/fpsyt.2016.00116, PMID 27445872, PMCID PMC4921745.

Pompili M, Giordano G, Luciano M, Lamis DA, Del Vecchio V, Serafini G. Unmet needs in schizophrenia. CNS Neurol Disord Drug Targets. 2017;16(8):870-84. doi: 10.2174/1871527316666170803143927, PMID 28782490.

Maroney M. An update on current treatment strategies and emerging agents for the management of schizophrenia. Am J Manag Care. 2020 Mar;26(3)Suppl:S55-61. doi: 10.37765/ajmc.2020.43012, PMID 32282175.

Hoff AL, Kremen WS. Neuropsychology in schizophrenia: an update. Curr Opin Psychiatry. Mar 2003;16(2):149-55. doi: 10.1097/00001504-200303000-00003.

Thaker GK, Carpenter WT Jr. Advances in schizophrenia. Nat Med. 2001;7(6):667-71. doi: 10.1038/89040, PMID 11385502.

Lee HJ, Choi BH, Choi JS, Hahn SJ. Effects of cariprazine on hERG 1A and hERG 1A/3.1 potassium channels. Eur J Pharmacol. 2019 Jul 5;854:92-100. doi: 10.1016/j.ejphar.2019.04.006. PMID 30954564.

Yamada Y, Matsumoto M, Iijima K, Sumiyoshi T. Specificity and continuity of schizophrenia and bipolar disorder: relation to biomarkers. Curr Pharm Des. 2020;26(2):191-200. doi: 10.2174/1381612825666191216153508, PMID 31840595, PMCID PMC7403693.

Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Nemeth G. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019;29(1):127-36. doi: 10.1016/j.euroneuro.2018.10.008. PMID 30470662.

Callaly E, Walder K, Morris G, Maes M, Debnath M, Berk M. Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Rev Med Chem. 2015;15(5):355-65. doi: 10.2174/1389557515666150324122026, PMID 25807948.

Vieta E, Sanchez Moreno J. Acute and long-term treatment of mania. Dialogues Clin Neurosci. 2008;10(2):165-79. doi: 10.31887/DCNS.2008.10.2/evieta, PMID 18689287.

Mamdani F, Groisman I, Alda M, Turecki G. Pharmacogenetics of bipolar disorder. Curr Pharmacogenomics. 2003;1(4):269-76. doi: 10.2174/1570160033476214, doi: 10.2174/1570160033476214.

National Institute of Mental Health. Bipolar disorder. Available from: https://www.nimh.nih.gov/health/topics/bipolar-disorder. [Last accessed on 09 Sep 2022].

DelBello MP, Adler CM, Cerullo MA, Fleck DE, Strakowski SM. Bipolar disorder, Ed(s): Larry R. Academic Press; 2009. p. 201-7. doi: 10.1016/B978-008045046-9.00493-9.

Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296-302. doi: 10.1016/j.jad.2014.11.018, PMID 25532076.

National Center for Biotechnology Information. PubChem compound summary for CID 11154555. Available from: https://pubchem.cariprazine.ncbi.nlm.nih.gov/compound/cariprazine. [Last accessed on 15 Apr 2022]

McCormack PL. Cariprazine: first global approval. Drugs. 2015 Nov;75(17):2035-43. doi: 10.1007/s40265-015-0494-7, PMID 26510944.

Mazza M, Marano G, Traversi G, Carocci V, Romano B, Janiri L. Cariprazine in bipolar depression and mania: state of the art. CNS Neurol Disord Drug Targets. 2018;17(10):723-7. doi: 10.2174/1871527317666180828120256, PMID 30152291.

De Berardis D, Orsolini L, Iasevoli F, Prinzivalli E, de Bartolomeis A, Serroni N. The novel antipsychotic cariprazine (RGH-188): state-of-the-art in the treatment of psychiatric disorders. Curr Pharm Des. 2016;22(33):5144-62. doi: 10.2174/1381612822666160701084447, PMID 27396597.

Gedeon R. Cariprazine is well tolerated in the early stage of schizophrenia and has a positive effect on engagement compared to another antipsychotic. Available from: http://www.prnewswire/news-releases/gedeon-richter-cariprazine-is-well-tolerated-in-the-early-stage-of-schizophrenia-and-has-a-positive-effect-on-engagement-compared-to-another-antipsychotic-301266936.html. [Last accessed on 13 Apr 2021]

Riedesser S, Gahr M. Cariprazine: experiences from a naturalistic treatment setting. Nervenheilkunde. 2020;39(4):238-41. doi: 10.1055/a-0988-2039.

Agai Csongor E, Domany G, Nogradi K, Galambos J, Vago I, Keseru GM. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett. 2012 May 15;22(10):3437-40. doi: 10.1016/j.bmcl.2012.03.104, PMID 22537450.

Findlay LJ, El-Mallakh PL, El-Mallakh RS. Cariprazine for the treatment of bipolar disorder. Perspect Psychiatr Care. 2017 Jul;53(3):148-55. doi: 10.1111/ppc.12150, PMID 27059102.

Jiali Ye Y, Liu Kaihang, Zhou X, Gu J, Hu X. Crystal structures and thermodynamic properties of new atypical antipsychotic cariprazine and its hydrochloride. Crystallogr Rep. 2018;63(6):930-6. doi: 10.1134/S1063774518060147.

Gyertyan I, Kiss B, Saghy K, Laszy J, Szabo G, Szabados T. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925-35. doi: 10.1016/j.neuint.2011.07.002. PMID 21767587.

Mazza M, Marano G, Traversi G, Carocci V, Romano B, Janiri L. Cariprazine in bipolar depression and mania: state of the art. CNS Neurol Disord Drug Targets. 2018;17(10):723-7. doi: 10.2174/1871527317666180828120256, PMID 30152291.

Shrivastava A, Mittal A. A mini review on characteristics and analytical methods of otilonium bromide. Crit Rev Anal Chem. 2022;52(7):1717-25. doi: 10.1080/10408347.2021.1913983, PMID 34039224.

Shrivastava A, Sharma S, Kaurav M, Sharma A. Characteristics and analytical methods of mannitol: an update. Int J App Pharm. 2021;13(5):20-32. doi: 10.22159/ijap.2021v13i5.42068.

Shrivastava A. Characteristics and analytical methods of novel PDE5 inhibitor avanafil: an update. Hacettepe University Journal of the Faculty of Pharmacy. 2022:134-47. doi: 10.52794/hujpharm.1017182.

Robert P. Plain radiographic imaging. Clinical Imaging. 3rd ed Marchiori DM, editor. Mosby; 2014. p. 1-5. doi: 10.1016/B978-0-323-08495-6.00001-4.

Lewis ML. Heat transfer mechanisms. In: Woodhead Publishing Series in Food Science, Technology and Nutrition, Physical Properties of Foods and Food Processing Systems. Woodhead Publishing; 1999. p. 246-91. doi: 10.1533/9781845698423.246.

Cid MM. Structure elucidation in organic chemistry: the search for the right tools. Bravo J; 2022. doi: 10.1002/9783527664610.

Shrivastava A. UV spectrophotometry: applications in adulteration analysis of drugs, frontiers in drug safety adulteration analysis of some foods and drugs. 2018;1:80-90. doi: 10.2174/9781681086750118010008.

Meszaros GP, Agai Csongor E, Kapas M. Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl-and didesmethyl-RGH-188 in human plasma and urine. J Pharm Biomed Anal. 2008;48(2):388-97. doi: 10.1016/j.jpba.2007.12.016, PMID 18242914.

Gyertyan I, Kiss B, Saghy K, Laszy J, Szabo G, Szabados T. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925-35. doi: 10.1016/j.neuint.2011.07.002. PMID 21767587.

Toth M, Varrone A, Steiger C, Laszlovszky I, Horvath A, Kiss B. Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist 11C cariprazine: an in vivo positron emission tomography study in nonhuman primates. Synapse. 2013;67(5):258-64. doi: 10.1002/syn.21631, PMID 23238770.

Ablordeppey S, Ofori E. Antipsychotic agents. In: Abraham DJ, Myers M, editors. Burger’s medicinal chemistry, drug discovery and development. 8th ed. John Wiley and Sons, Inc; 2021. doi: 10.1002/0471266949.

Ribeiro ELA, de Mendonça Lima T, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018;74(10):1215-33. doi: 10.1007/s00228-018-2498-1. PMID 29905899.

Scarff JR. Cariprazine for schizophrenia and bipolar disorder. Innov Clin Neurosci. 2016;13(9-10):49-52. PMID 27975000.

Qassim S, Boura F, Al-hariri Y. Public knowledge and attitude toward depression and schizophrenia: findings from the quantitative study in UAE. Asian J Pharm Clin Res. 2018;11(7):402-6. doi: 10.22159/ajpcr.2018.v11i7.26160.

Arya A, Sindhwani G, Kadian R. Neurotransmitter and brain parts involved in schizophrenia. Asian J Pharm Clin Res. 2018;11(6):4-11. doi: 10.22159/ajpcr.2018.v11i6.24557.